Apotex announced the commercial launch of Apo‑Semaglutide Injection™ – a generic equivalent of Ozempic.
Apo‑Semaglutide Injection is approved in 2 mg and 4 mg prefilled pen formats, providing:
- 0.25 mg or 0.5 mg doses (2 mg pen; 0.68 mg/mL)
- 1 mg doses (4 mg pen; 1.34 mg/mL)
Apo-Semaglutide Injection™ is administered using a prefilled pen with instructions for use consistent with brand‑name semaglutide, supporting familiarity for patients and health care professionals, facilitating a smooth transition.
In Canada, Apo‑Semaglutide Injection is indicated for the once‑weekly treatment of adults with type 2 diabetes mellitus to improve glycemic control, in combination with diet and exercise.
"The launch of Apo‑Semaglutide Injection reflects our Canadian roots and our dedication to making important treatment options more accessible to people across Canada," said Martin Arès, President, Apotex Canada. "With product now available, we are proud to offer a high‑quality, affordable option that supports patients, prescribers, and contributes to a strong and reliable healthcare system for Canadians."
Developed in partnership with Orbicular Pharmaceutical Technologies, Apo‑Semaglutide Injection underwent Health Canada's standard regulatory review for peptide medicines.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!